Biotech and life sciences companies are racing to adopt artificial intelligence across drug development, clinical trials, and manufacturing. At the same time, regulators are catching up fast. FDA AI governance has moved from a theoretical concern to a documented, board-level requirement. CIOs, quality leaders, and compliance teams now need a clear plan for meeting new FDA expectations.
This article breaks down what the FDA’s recent guidance actually requires. It covers why FDA AI governance matters for your GxP validation strategy. It also shows how to build a framework your organization can defend during an audit.
Why FDA AI Governance Is Now a Board-Level Priority
The FDA has authorized more than 1,000 AI-enabled medical devices as of December 2024. In addition, drug and biologic submissions using AI components have also surged. Specifically, CDER reviewed over 500 such submissions between 2016 and 2023. As a result, this growth explains why FDA AI governance is no longer optional for life sciences leaders.
Meanwhile, regulatory pressure is building alongside adoption. Gartner’s 2024 AI Operating Model surveys found only 9% of life science companies employ a dedicated AI ethicist. By comparison, payers reported 17%, and providers reported just 6%. Consequently, that gap creates real exposure. Without clear ownership, organizations struggle to demonstrate that AI-driven decisions meet safety and quality standards.
Looking ahead, Gartner projects that by 2028, 70% of life science companies will have built a formal AI validation framework. Otherwise, companies that wait risk falling behind both regulators and competitors. Overall, strong FDA AI governance protects patient safety while also protecting your ability to bring products to market on schedule.
What the FDA’s New AI Guidance Actually Covers
The FDA published two major draft guidance documents in January 2025, both shaping the current FDA AI governance landscape.
Drug and Biological Product Guidance
On January 7, 2025, the FDA issued new draft guidance on AI in drug and biological products. This guidance introduces a seven-step credibility assessment framework. Sponsors must define the regulatory question their AI model addresses. They must also assess model risk and document a credibility assessment plan.
Specifically, the guidance covers AI use across nonclinical, clinical, postmarketing, and manufacturing phases. It applies whenever an AI model’s output supports a regulatory decision about safety, effectiveness, or quality.
AI-Enabled Medical Device Guidance
In addition, the FDA released Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations that same week. This guidance takes a total product life cycle approach. Furthermore, it addresses transparency, bias monitoring, and data drift across a device’s full lifespan.
Joint FDA-EMA Guiding Principles
In January 2026, CDER and CBER officials worked with the European Medicines Agency on this topic. Together they published ten shared principles for responsible AI use. This transatlantic alignment signals where global FDA AI governance expectations are heading next.
The Four Pillars Behind Strong FDA AI Governance
Gartner research identifies four pillars that support responsible AI governance in healthcare and life sciences. Each pillar reinforces the others, and together they form a complete FDA AI governance model.
Ethical and Responsible AI
Responsible AI protects against unintended harm. Specifically, core principles include data privacy, fairness, transparency, and accountability. Above all, patient-centered design should sit at the middle of every decision your team makes.
Compliance, Legal and Risk
The regulatory environment shifts constantly across states and countries. Therefore, your legal team needs a seat at the table early. In particular, contract language with AI vendors should clearly assign responsibility for model performance and errors.
Workforce Impact and Adoption
AI changes how clinicians, quality engineers, and compliance staff do their jobs. As a result, training programs must help employees interpret AI outputs correctly. At the same time, end users need to trust the tools without over-relying on them blindly.
Model Validation and Verification
Bias and data drift threaten AI reliability over time. Continuous monitoring, algorithm documentation, and model cards all support this pillar. Coretelligent’s AI governance checklist for CFOs offers a practical starting point for assessing gaps across these four pillars.
Rethinking GxP Validation for AI Systems
Conventional GxP validation assumes deterministic software. AI breaks that assumption, which forces a rethink of how FDA AI governance intersects with quality systems.
Five Dimensions of Change
Gartner research identifies five dimensions where AI-augmented solutions diverge from conventional software. These are algorithm behavior, architecture, data input and output, testing focus, and system life cycle. Specifically, AI models are probabilistic rather than deterministic. Consequently, they may hallucinate or drift under changing conditions. Meanwhile, architecture is often distributed across external APIs rather than self-contained.
Testing focus shifts from static verification to ongoing model validation. System life cycle management becomes continuous instead of a one-time event. Teams should apply risk-based validation, reserving full validation rigor for high-risk use cases while allowing lighter oversight for low-risk applications. Coretelligent’s guide on regulatory compliance in life sciences explores how this shift affects broader compliance planning.
The Validation Accountability Spectrum
Gartner defines five levels of validation accountability, ranging from fully human-accountable to fully autonomous. Most Gartner clients agree that for GxP processes, only Level 2, described as an amplified human model, is currently feasible. In this model, AI generates work product, but a human verifies every output against source data.
By comparison, Level 3 is described as machine-assisted. It may be possible for tightly controlled machine learning models or domain-specific language models. However, fully autonomous AI remains impractical for regulated GxP processes today. Therefore, teams building an FDA AI governance program should map their own AI use cases against this spectrum before deployment.
Building an FDA AI Governance Framework That Holds Up
The FDA’s computer software assurance guidance gives CIOs a risk-based methodology for GxP validation. This approach lets teams designate testing rigor based on actual risk. Teams no longer need to apply the same rigid process to every system. Pairing computer software assurance with new AI-specific risk factors creates a more defensible validation strategy.
Quality and IT teams must collaborate closely here. Validation experts, data ethicists, and legal counsel each bring pieces of the puzzle. Coretelligent’s overview of governance, risk, and compliance strategy explains how these functions fit together operationally.
New GenAI-powered tools can also help validate AI itself. Vendors are building explainability reports, automated testing, and drift detection directly into their platforms. These tools reduce manual burden while strengthening documentation. A 2026 academic review highlights both strengths and open questions in the FDA’s current approach. The structured, risk-based credibility framework earns particular praise as a meaningful step forward. Read the full analysis in the Journal of Chemistry.
Practical Next Steps for Biotech and Life Sciences Teams
Strong FDA AI governance does not happen by accident. It requires deliberate investment in people, process, and technology well before an audit forces the issue.
Start by inventorying every AI system currently in use across your organization. Map each one against the validation accountability spectrum described above. Identify which systems touch patient safety, drug quality, or regulatory submissions directly.
Next, assign clear ownership. Someone in your organization needs explicit responsibility for FDA AI governance. That person might hold the title of AI ethicist, compliance officer, or CIO. Document decisions as you make them, since documentation is what regulators and auditors will ask to see first.
Treat FDA AI governance as an ongoing process rather than a one-time project. Guidance will keep evolving, and your framework needs to evolve with it. Life sciences organizations that build this muscle now will move faster later, with fewer surprises during regulatory review.